Sarcopenia, the progressive loss of skeletal muscle mass and function, is a major driver of frailty and poor outcomes in aging and metabolic disease. This session brings together three perspectives on combating sarcopenia: nicotinamide riboside supplementation to counteract drug-induced lipodystrophy, a novel CA3–AKT–GSK3β–PGC1α pathway rejuvenating aged satellite cells to enhance muscle regeneration, and strategies to reprogram mitochondrial metabolism to combat sarcopenia. Together, these talks highlight converging metabolic, mitochondrial, and regenerative approaches opening new therapeutic avenues for sarcopenia.